ICON Releases NONMEM® 7

Dublin, Ireland, October 9th, 2009 – ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that its Development Solutions division has released a new version of NONMEM®, ICON’s non-linear, mixed effects modelling tool for Population Pharmacokinetic/Pharmacodynamic (PK/PD) data analysis. 

NONMEM 7 includes a new suite of statistical methods to support more complex models for analysing Population PK/PD data and provides a more comprehensive range of classical estimation methods. Many of the new complex models, which are increasingly being developed by scientists to further drug development programs, can not be analysed using classical estimation methods. However, with NONMEM 7 the efficiency and incidence of success of analysing both traditional and complex PK/PD models is greatly improved.

“NONMEM is recognised worldwide as the gold standard platform for analysing Population Pharmacometric data,” commented Dr. Thomas Frey, President, ICON Development Solutions. ”This latest version cements NONMEM’s leadership by providing the industry’s most comprehensive suite of software tools that can support current and future population-based data analyses. We have also incorporated a lot of our users’ feedback and have greatly enhanced the product’s usability.”
 

About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has over 7,100 employees, operating from 71 locations in 38 countries.